Crescendo Biologics Appoints Edward J. Stewart as Chief Business
... Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer
Cambridge, UK, 14 June 2017 – Crescendo Biologics Ltd (Crescendo), a company developing highly
potent and differentiated Humabody® therapeutics, today announced that Edward J. “Tad” Stewart has
joined the company as Chief Busin ...
Oncolys BioPharma and Medigen Biotechnology Enters Strategic
... Yasuo Urata, President and Chief Executive Officer of Oncolys.
“With our prior experience and track records in successfully conducting liver cancer
trials under the auspice of US FDA, we believe the collaboration between Medigen and
The sector inquiry - Open Research Exeter
... provided through the use of SPCs. Their
conduct was considered to be solely for the
purpose of keeping manufacturers of generic
products, wrongfully, away from the market by
acquiring SPCs in a manner contrary to the
regulation.31 AstraZeneca contended that their
behaviour was not intended to mislea ...
... exclusive rights for the purpose of developing and commercializing AZD7986 (the “Compound”). The Compound is a novel oral inhibitor of
dipeptidyl peptidase I (“DPP1”). DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases, which play a key role in
pulmonary diseases such as ...
Form 6-K ASTRAZENECA PLC - N/A Filed: December 12, 2013
... LD is a group of rare syndromes often associated with severe metabolic abnormalities and significant morbidity and mortality. It is
estimated to affect only a few thousand people worldwide. LD is heterogeneous in presentation and often occurs at an early age during childhood or in early adulthood. T ...
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales (after Pfizer, Sanofi, Novartis, Merck & Co., Roche and GlaxoSmithKline) and has operations in over 100 countries.AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including of Cambridge Antibody Technology (in 2006), MedImmune (in 2007), and Spirogen (in 2013).AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £54.8 billion as of 1 August 2014, the sixth largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange.